Generic Name and Formulations:
Lidocaine 5%; adhesive patch.
Indications for LIDODERM:
Apply to intact skin, covering most painful area. To adjust dose, cut patches before removing release liner. Remove if irritation or burning occurs; do not reapply until irritation subsides. May apply up to 3 patches at once for up to 12hrs of a 24-hour period. Hepatic impairment or debilitated: use smaller treatment areas.
Do not apply to broken or inflamed skin. Avoid eyes, mucous membranes, longer duration of application, and application of more than 3 patches. Do not ingest; may be toxic to children and pets. Hepatic disease. Small patients. Pregnancy (Cat.B). Labor & delivery. Nursing mothers.
Toxicity may be potentiated by Class I antiarrhythmics (e.g., tocainide, mexiletine). Additive effects with other local anesthetics.
Local effects (e.g., erythema, edema), allergic reactions (e.g., urticaria, angioedema, bronchospasm).
Patches (10cm x 14cm)—30
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|